IND vs. CTA: Two Filings, One Data Set

How do the two filings actually differ?

In who decides and how the clock runs. An IND is a submission to a single agency, and a study may proceed after 30 days unless the FDA places it on clinical hold. That default-permission structure means the sponsor controls timing to a considerable degree. An EU application under the Clinical Trials Regulation is submitted once through a common portal but assessed in two parts: a scientific part coordinated across the member states concerned by a single reporting member state, and a national part covering ethics, informed consent and local arrangements. The result is an explicit authorisation decision rather than a silent clearance, and the timetable includes defined windows for questions and responses that the sponsor must be resourced to answer quickly.

What genuinely transfers between them?

Most of the science, and less of the packaging than sponsors hope. The non-clinical pharmacology and toxicology, the manufacturing and quality data, and the protocol's scientific design generally transfer intact; ICH harmonisation is doing real work here. What does not transfer is the assembly. The EU application expects an investigational medicinal product dossier structured to its own expectations, and it expects lay-language and consent documentation prepared per member state and per language. Sponsors also underestimate the sponsor-obligation differences: EU legislation places specific duties on the sponsor around safety reporting and trial registration that have no direct IND analogue.

Which should you file first?

Usually whichever market is on the critical path, but the more useful question is what you build once. Sponsors who intend to run in both regions and plan for it from the start write the non-clinical summaries and the quality module to serve both, and budget the EU-specific assembly and translation as a known workstream rather than a surprise. Sponsors who file the IND first and treat the EU application as a conversion exercise typically lose a quarter to document restructuring and translation they did not schedule. Neither route is wrong; only one of them is planned.

Frequently asked questions

Can we use the same protocol document for both?

The scientific protocol can generally be common, and keeping it common is desirable for data comparability. What has to be region-specific is the surrounding documentation: consent forms, participant-facing material, and national-part submissions per member state.

Does an FDA clinical hold affect our EU application?

Not automatically as a legal matter, but it is material information. Sponsors are expected to be transparent with regulators about the status of the programme elsewhere, and a hold that reflects a safety concern will be relevant to the EU assessment.

How long does EU authorisation take?

The Clinical Trials Regulation sets defined assessment timetables with fixed windows for validation, assessment and any requests for further information. The elapsed time in practice depends heavily on how quickly a sponsor answers questions within those windows.

Sources

1. Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use, European Union. eur-lex.europa.eu
2. 21 CFR Part 312 — Investigational New Drug Application, US Food and Drug Administration. ecfr.gov

Pending scientific review. This briefing summarises published regulatory guidance and has not yet been signed off by a named subject-matter expert. Verify against the primary sources below before relying on it.

Running the same programme in two regions?

We map what can be built once and what has to be built twice, before the duplication becomes a schedule problem.

Explore Regulatory Affairs ➔